Table 1 shows the descriptive statistics of the studied samples for different NSCLC stages, healthy control subjects and patients withCOPD, median and mean (SD, CI 95%) levels of tumor markers CA-62, CEA, CA 15-3, NSE, CA-125, CA-19-9, CYFRA 21-1, and SCC. This evidence concerns the gene ENO2 and neoplasm.